ERBB2 and breast cancer: Remarkable successes in this field include the FDA approval of Trastuzumab for breast cancer patients overexpressing the HER2 protein [1] and Erlotinib for metastatic non-small cell lung cancer patients (NSCLC) with exon 19 deletion or exon 21 (L858R) substitution in the EGFR gene [2].